Abstract
Forty-nine women with progressive metastatic breast cancer, extensively pretreated, received mitomycin C 12 mg/m2 and vinblastine 6 mg/m2 intravenously every 3 weeks. Eleven patients responded, giving a response frequency of 22%. Considering only the 40 patients evaluable after two or more courses of treatment, the response frequency is 27.5%. Responses occurred predominantly at soft tissue sites. Subjective toxicity was mild. © 1985.
| Original language | English |
|---|---|
| Pages (from-to) | 1475-1477 |
| Number of pages | 2 |
| Journal | European Journal of Cancer and Clinical Oncology |
| Volume | 21 |
| Issue number | 12 |
| Publication status | Published - Dec 1985 |
